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State-of-the-Art PaperEffect of Valve Design on the Stent Internal
Diameter of a Bioprosthetic ValveA Concept of True Internal Diameter and Its Implications for
the Valve-in-Valve Procedure
Vinayak N. Bapat, MD, Rizwan Attia, MD, Martyn Thomas, MD
London, United KingdomThe goal of this study was to provide a measurement of the true internal diameter (ID) of various surgical
heart valves (SHV) to facilitate the valve-in-valve (VIV) procedure. During a VIV procedure, it is important to
choose the right of the transcatheter heart valve (THV). Most users use the stent ID of an SHV to select
the appropriate THV size. Echocardiography and computed tomography measurements are not yet
standardized for measuring the ID of a variety of SHVs. Hence, we measured the true ID of SHV to assess the
effect of valve design on the stent ID. Thirteen types of stented and 3 types of stentless valves were
evaluated. True ID measurements were obtained using calipers and Hegar dilators. These were compared
with the stent ID measurements. Fluoroscopy was used to conﬁrm the impact of SHV designs on the true
ID. Caliper measurements were found to be inaccurate and are hence not recommended. Hegar dilator
measurements revealed a trend of reduction in stent ID. Porcine valves were most affected by their design,
with reduction in the stent ID by at least 2 mm; pericardial valves with leaﬂets sutured inside the stent had
the stent ID reduced by at least 1 mm, and SHV with leaﬂets sutured outside the stent had no effect on
stent ID. In the majority of SHV designs, there is a reduction in the stent ID as a result of leaﬂet tissue. This is
important in borderline sizes to avoid problems associated with oversizing and also to conﬁrm suitability for
the VIV procedure in the smaller label sizes of SHV. (J Am Coll Cardiol Intv 2014;7:115–27) ª 2014 by the
American College of Cardiology FoundationTranscatheter aortic valve implantation (TAVI) has
established itself as an accepted therapy for inop-
erable and high-risk patients with calciﬁc aortic
stenosis (1). Clinical need has led to the use of this
technology in treating degenerated bioprosthetic
surgical heart valves (SHV) to avoid redo open
heart surgery (2). Multiple reports of valve-in-valve
(VIV) procedures have appeared in the literature
over the last 2 years, with substantial experience
being acquired in treating a degenerated SHV
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15, 2013, accepted October 24, 2013.experience in treating degenerated SHV in pul-
monary and tricuspid positions (2–11).
This therapy area continues to grow rapidly
because VIV treatment appears promising when
compared with a redo open heart operation, due to
its less invasive nature. One of the important de-
terminants of immediate and long-term success of
this novel treatment is choosing the right size of the
transcatheter heart valve (THV) for a given SHV
type and size. In a native aortic valve, measurements
are performed at the level of the aortic annulus to
determine the size of the THV (12). When per-
forming a VIV procedure, the majority of current
users use the stent internal diameter (ID) of an
SHV to select the appropriate THV size (2–5).
However, the SHV design may have an impact on
this measurement because of the leaﬂet tissue
mounted within the stent frame. We evaluated the
effect of valve design on stent ID and discuss the
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116concept of the true ID of an SHV, which is the relevant ID
for the VIV procedure. We also brieﬂy discuss sizing con-
siderations for a VIV procedure in the aortic versus the mitral
position.
Methods
Thirteen types of stented and 3 types of stentless aortic SHV
of all sizes were obtained from various manufacturers
(Table 1, Fig. 1). The 3 types of stentless aortic SHV
studied were those implanted as aortic roots (Fig. 2).
Stentless valves, which are implanted in a subcoronary po-
sition within a native aortic root, were excluded because they
essentially behave like native aortic valves and take up the
dimensions of the root in which they are implanted (Fig. 2).
Stent ID. We have previously published the stent ID of all
SHV along with other dimensions (13). The industry
standard when reporting the stent ID is the ID of the stent
frame when covered with fabric or pericardium but without
the valve leaﬂets (Fig. 3).Abbreviations
and Acronyms
CE = Carpentier-Edwards
CT = computed tomography
ID = internal diameter
SHV = surgical heart valve(s)
TAVI = transcatheter aortic
valve implantation
THV = transcatheter heart
valve(s)True ID. True ID was deﬁned as
the ID of the inﬂow of the SHV.
Caliper measurements. An at-
tempt was made to obtain the ID
measurements with the use of a
Vernier caliper (Fig. 4). The caliper
was introduced through the inﬂow
of the SHV, and measurements
were obtained with minimal dis-
tortion. At least 2 measurements
were obtained for each SHV, and 3
operators independently measured
all sizes of each type of SHV.Hegar dilator measurements. We used Hegar dilators with
increments of 0.5 mm to measure the true ID. The Hegar
dilator has a conical tip; thus, it can be easily introduced
within an SHV (Fig. 5) from the valve inﬂow. The main
body of the dilator is a perfect circle in cross section and,
hence, gives an exact diameter. Measurements were per-
formed using incremental sizes of Hegar dilators, and the
largest size of the dilator that could be placed within an SHV
was noted for each SHV (Fig. 5). Measurements were per-
formed by 3 operators independently.
Conﬁrmation of hypotheses using ﬂuoroscopy. SHV are
essentially of 3 types depending upon the leaﬂet material and
placement of the leaﬂets: 1) porcine valve with leaﬂets su-
tured inside of the stent; 2) pericardial valve with bovine
pericardial leaﬂets sutured inside of the stent; and 3) peri-
cardial valve with bovine pericardial leaﬂets sutured outside
of the stent. To assess the effects of valve design on the stent
ID, 1 SHV of each type with a radio-opaque stent frame
was chosen. These were the Carpentier-Edwards (CE)
standard, Perimount (Edwards Lifesciences, Irvine, Califor-
nia), and Trifecta (St. Jude Medical, St. Paul, Minnesota),
VIV = valve-in-valverespectively. A CoreValve THV (Medtronic, Minneapolis,
Minnesota) was implanted within each of these, and the
degree of separation between the radio-opaque stent frame
and the CoreValve stent frame (inﬂow portion) was
observed; this essentially is the difference between the stent
ID and the true ID.
Results
True ID measurement with calipers. Because the SHV can be
easily distorted with the lateral push of the caliper arms,
there was a large variability in these measurements (from 0.5
to 2 mm) (Fig. 4). This was particularly true for SHV de-
signs such as the CE porcine valve, which has an asymmetric
leaﬂet structure (Fig. 4) and lacks a complete polymer/metal
ring at the base of its frame. This was also observed with the
stentless valves because they lack a rigid base. An attempt
was made to obtain measurements without distorting the
valve, but the interoperator variability was still large; thus, we
did not use this method for measurement of the true ID.
True ID measurement with Hegar dilators. STENTEDAORTICSHV.
The true ID was smaller than the stent ID in the majority of
SHV (Table 2). There was no interoperator variability found
in the Hegar dilator measurements except for the CE
porcine valve, where 0.5-mm variability was noticed only in
the larger sizes for the reasons mentioned in the preceding
text. In these cases, we have taken the largest measurement
for analysis. We found the following trends in the reduction
of the true ID depending on the design of the SHV:
1. Porcine SHV: The porcine valve leaﬂets are always
sutured inside of the stent frame, and the true ID is at
least 2 mm less than the stent ID (Fig. 6A). Examples:
Hancock II (Medtronic), Mosaic (Medtronic), Aspire
(Vascutek, Inchinnan, United Kingdom), CE porcine
standard, CE porcine S.A.V. (Edwards Lifesciences),
Epic/Biocor (St. Jude Medical), and Epic/Biocor Su-
pra (St. Jude Medical).
2. Pericardial SHV with leaﬂets sutured inside of the
stent: The effect of the pericardial leaﬂets was less than
that of the porcine leaﬂets, and the difference between
true ID and stent ID was 1 mm (Fig. 6B). Examples:
Perimount (Edwards Lifesciences), Perimount 2700
(Edwards Lifesciences),Magna/Magna Ease (Edwards
Lifesciences), and Soprano (Sorin, Milan, Italy).
3. Pericardial SHV with leaﬂets sutured outside of the
stent: Because the leaﬂets were sutured outside of the
stent, the stent ID and the true ID were similar
(Fig. 6C). Examples: Mitroﬂow (Sorin) and Trifecta.
STENTLESS AORTIC SHV. Although there is variability be-
tween various manufacturers, the true ID was always smaller
than the labeled size (which corresponds to the root diameter)
(Table 2).
Table 1. SHV Characteristics
Manufacturer Valve Model Referred to as
Leaﬂet
Tissue
Relationship of Leaﬂets
to the Stent Frame
Stented SHV
Edwards Lifesciences (Irving, California) Carpentier-Edwards Perimount 2700 P2700 Pericardium Inside
Carpentier-Edwards Perimount Perimount Pericardium Inside
Carpentier-Edwards Perimount Magna and Magna Ease Magna Pericardium Inside
Carpentier-Edwards aortic porcine bioprosthesis CE porcine Porcine Inside
Carpentier-Edwards SupraAnnular (S.A.V.) aortic
porcine bioprosthesis
CE S.A.V. Porcine Inside
Medtronic (Minneapolis, Minnesota) Mosaic tissue valve Mosaic Porcine Inside
Hancock II tissue valve Hancock II Porcine Inside
St. Jude Medical (St. Paul, Minnesota) Epic (Biocor) valve Epic Porcine Inside
Epic Supra (Biocor Supra) valve Epic Supra Porcine Inside
Trifecta valve Trifecta Pericardium Outside
Sorin (Milan, Italy) Mitroﬂow Mitroﬂow Pericardium Outside
Soprano Armonia Soprano Pericardium Inside
Vascutek (Inchinnan, United Kingdom) Aspire Aspire Porcine Inside
Stentless SHVs
Edwards Lifesciences Prima root Prima Porcine root Inside
Medtronic Freestyle root Freestyle Porcine root Inside
St. Jude Medical Toronto SPV root Toronto SPV Porcine root Inside
CE ¼ Carpentier-Edwards; S.A.V. ¼ SupraAnnular porcine valve; SHV ¼ surgical heart valve.
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117Fluoroscopy. Fluoroscopy conﬁrmed the aforementioned
ﬁndings (i.e., the effect of leaﬂet mounting on the reduction
of stent ID). The degree of separation of a fully deployed
CoreValve THV was greater in the CE porcine standard
valve when compared with the Perimount SHV. In Trifecta,
the stent frame and CoreValve inﬂow were in approxima-
tion, conﬁrming the Hegar dilator ﬁndings (Fig. 7).Discussion
TAVI is now well established as a treatment modality for
aortic stenosis. A large body of experience is accumulating
with the VIV procedure using Sapien and Sapien XT valves
(Edwards Lifesciences) and CoreValve and Evolut valves
(Medtronic) (2–11). Because both of the valves were designed
for the aortic position, the largest experience within the VIV
ﬁeld has been in the treatment of degenerated aortic SHV
(2–8). Because of favorable early results, the indication has
slowly progressed to treating degenerated SHV in the mitral,
tricuspid, and pulmonary positions (9–11). However, recent
data reported in the global registry have raised doubts about
the utility of VIV in treating smaller label sizes of a variety of
SHV (14). This is due to the higher residual gradients
observed in SHV with label sizes 21 mm leading to
“patient–prosthesis mismatch.” Mismatch is well known to
be associated with a smaller reduction in gradients and less
satisfactory beneﬁts in terms of left ventricular systolic and
diastolic function and left ventricular mass regression. Theglobal registry also highlighted a 15.3% incidence of malpo-
sition and a 3.5% incidence of coronary obstruction (14).
Part of the problem is a limited understanding of the
various designs of the SHVs implanted in the last 2 decades
and their impact on the VIV procedure. One must take into
account the design of an SHV, the design of a THV, and
their interaction to achieve optimal results. Two important
determinants of immediate and long-term success of this
novel treatment are choosing the right THV size and
securing the THV in an optimal position within the SHV.
With limited sizes of THV available, one must choose a
correctly sized THV to match an SHV. Undersizing will
lead to a large paravalvular leak and/or embolization,
whereas oversizing will lead to incomplete expansion of the
THV, which can contribute to improper functioning and/or
higher residual gradients (14).
In a native aortic valve, the ID measurements are per-
formed at the level of the aortic annulus to determine the
size of the THV (1,12). These are obtained either by
transthoracic echocardiography, transesophageal echocardi-
ography, computed tomography (CT) scan, or balloon sizing
during the procedure (12,15). The THV size is then chosen
with a degree of oversizing to achieve secure ﬁxation. The
majority of TAVI users have extrapolated the same principle
when performing a VIV procedure (2–11). It is well known
that for a given native aortic annulus diameter, there is a
certain amount of variability in measurements obtained by
various modalities, and hence, the ID of an SHV measured
by these modalities may not be the same and may reﬂect
Figure 1. Images of Various SHV With Fluoroscopic Images for Stented Valves
All stentless valves and a few stented valves are not radio-opaque. (A to M) The ﬂuoroscopic image is shown on the right. (A) Perimount 2700. (B) Perimount.
(C) Magna. (D) CE porcine. (E) CE S.A.V. Continued on the next page
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Figure 1. Continued
(F) Mosaic. (G) Hancock II. (H) Epic. (I) Epic Supra. Continued on the next page
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119neither the stent ID nor true ID. Hence, the most common
measurement used today is the stent ID of an SHV provided
by the manufacturer (2,5).
It is well known that the same label size of various
stented SHV will differ in their stent ID measurements,
which has led to confusion in the past. However, multiple
publications have addressed this issue by compiling data
from the manufacturers to provide precise stent ID for all
label sizes of a variety of SHV (5,13). By convention,
however, the stent ID represents the ID of a bare stent
covered with fabric or pericardium only. It does not take
into account the effect of artiﬁcial leaﬂets sutured within
the stent (13). In a porcine SHV, the porcine leaﬂets are
always sutured inside the stent frame and, because of theirnatural hinge point mechanism, tend to encroach maxi-
mally inside the stent. Hence, the true ID is reduced by at
least 2 mm. We found that the range of reduction could be
2 to 4 mm and was largest in larger label sizes. The
variability is due to the fact that these leaﬂets are hand
sewn, and porcine leaﬂets from different pigs, even when
matched, can vary in their thickness. In a pericardial SHV,
the thickness of the bovine pericardium for the leaﬂets is
controlled and matched, and the way the pericardium is
sutured inside the stent leads to a reduction in the stent
ID by only 1 mm. In designs such as that of the Trifecta
and Mitroﬂow valves, because the sheet of pericardium is
wrapped outside the stent, the leaﬂets have no effect on the
stent ID.
Figure 1. Continued
(J) Trifecta. (K) Mitroﬂow. (L) Soprano. (M) Aspire. Continued on the next page
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120The implications of these ﬁndings are 4-fold:
1. When treating borderline sizes, especially with porcine
SHV, use of the true ID instead of the stent ID should
lead to choosing a smaller THV size than initially
planned. For example, label size 25 of Hancock II has
a stent ID of 22.5 mm and, hence, would point toward
the use of Sapien/Sapien XT size 26. However, the
true ID is 20.5 mm, and hence, the correct size of
Sapien/Sapien XT would be 23. A similar example for
CoreValve usage concerns label size 27 of the Epic,
where the stent ID (25 mm) would direct one to theuse of a size 29 CoreValve, but the true ID (22.5 mm)
points to the use of a size 26 CoreValve.
2. When treating labeled SHV sizes 21 mm, although
the label size and/or stent ID appear adequate, a look
at the true ID may reveal them to be unsuitable for
VIV treatment. For example, Hancock II size 21 has a
true ID of 16.5 mm, and hence, if treated with either
Sapien size 23 or Evolut size 23, will result in a size
mismatch and high residual gradients. This is also true
for pericardial valves with a small true ID such as
Perimount size 19 (true ID 17 mm). This ﬁnding also
Figure 1. Continued
(N) Prima root. (O) Freestyle root. (P) Toronto SPV root. CE ¼ Carpentier-Edwards; S.A.V. ¼ SupraAnnular porcine valve; SHV ¼ surgical heart valves.
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121explains why the incidence of high gradients in the
global registry (mean gradient 20 mm Hg) was
28.4%, and the gradients were higher after a VIV in
SHV sizes 21 mm. THV are available in multiple
sizes and have a lower and upper limit of diameter
tolerance recommended by the manufacturer. We have
used the same sizing guidelines for recommending use
of a THV in a given SHV (Table 2). Although clinical
cases have been performed, we felt that caution should
be exerted when evaluating these cases for VIV. If
implanted in a smaller diameter, either native aorticannulus or within a degenerated SHV, it may result in
suboptimal function and higher residual gradients.
3. Oversizing can lead to outward deﬂection of the
calciﬁed leaﬂets, which will increase the chance of
coronary obstruction. This risk will be higher if the
sinuses are shallow and with certain designs in which
the leaﬂets are outside of the stent frame (14,16,17).
4. Larger-sized SHV may still be suitable for VIV and
may, in practice, end up with the best results because
of having the least chance of a mismatch. For example,
size 29 Magna and Trifecta have a true ID of 27 and
Figure 2. Schematic Diagram Demonstrating 2 Methods of Implanting Stentless Valves and Their Relative Risk of Coronary Obstruction During a VIV Procedure
The large arrows point to the suture line, and the small arrows to the coronary ostia. (A) Subcoronary implantation of stentless valve external appearance.
(B) Subcoronary implantation visualized from within the aorta demonstrating the proximity of the suture line to the coronary ostia. (C) Stentless valve implanted as a
root replacement. VIV ¼ valve-in-valve.
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12226 mm, respectively, and can be treated with either
size 29 Sapien/Sapien XT or CoreValve size 31.
The stentless SHV design also poses certain challenges
during a VIV procedure. The lack of radio-opaque markers
increases the chances of malposition (2,14). The lack of
support for anchoring, compared with stented SHV, can also
contribute to embolization of the THV because the
distensibility of the aortic root is maintained (18). Stentless
valves are also associated with a higher risk of coronary
obstruction, because one may need to err on the side of
choosing a larger THV for a given diameter to ensure secure
anchoring. This was observed in the global registry, which
reported the highest incidence of coronary obstruction in the
stentless valves (14,19). However, we feel that the risk of
coronary obstruction is higher in stentless valves implanted
as a subcoronary implantation (e.g., the O’Brien [CryoLife,
Atlanta, Georgia], Freedom solo [Sorin], and Toronto SPV
[St. Jude Medical] valves), where the suture line is close to
the native coronary ostia (Fig. 1A), than in those implantedFigure 3. Effect of Leaﬂet Mounting on ID of the Stent Frame
(A) Outﬂow view of a surgical valve stent. (B) Outﬂow view of a surgical valve stent w
valve stent with leaﬂets. ID ¼ internal diameter.as root (e.g., Edwards Prima, Medtronic Freestyle root, and
Toronto SPV root valves), where the native coronary arteries
are implanted high on the sinuses (Fig. 1B and 1C). One
should always exercise caution when treating stentless valves,
because the mortality associated with coronary obstruction is
very high (14).
Three other issues need to be highlighted:
1. In day-to-day practice, a patient may present without
details of the SHV implanted. In these patients, one
can identify the type of SHV using the ﬂuoroscopic
guide, but it is not possible to identify the size of the
SHV (13). Because various noninvasive methods,
including ﬂuoroscopy, echocardiography, and CT
scan, may not accurately measure the true ID, one
should use on-table balloon aortic valvuloplasty
assessment if the size of the SHV is not known (20).
We are currently investigating and characterizing each
of the SHV designs to assess the impact of various
noninvasive modalities on ID measurements.ith leaﬂets. (C) Inﬂow view of a surgical valve stent. (D) Inﬂow view of a surgical
Figure 4. Vernier Caliper Measurements of True ID
(A) CE porcine standard valve outﬂow demonstrating oval shape. (B) Caliper positioned within the inﬂow of the SHV. (C) Subtle distortion of the SHV caused by the
caliper, which can lead to incorrect measurement. Measurement 1: 22.31 mm. (D) Measurement 2: 25.74 mm, highlighting the effect of the distortion. Abbreviations as
in Figures 1 and 3.
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1232. Although ID is the most important measurement used
to choose a size of THV when treating a native aortic
valve and an SHV, the height of the SHV may also
play an important role. This is relevant only for the
Sapien XT THV because all sizes of CoreValve are
taller than any size of SHV. It is not the stent height,
but the leaﬂet height and type of leaﬂets (i.e., porcine
or pericardial), that is important. Leaﬂet height of an
SHV increases with its labeled size. Adequate leaﬂet
cover is achieved in the majority of combinations with
Sapien XT THV because for a larger SHV size, one
chooses a large Sapien XT valve. This may, however,igure 5. Hegar Dilator Measurements of True ID
egar dilator highlighting the conical tip (thin arrow) and circular shaft (thick
rrow) once it is engaged within the SHV inﬂow to give a correct measure-
ent of true ID, 21 mm in this instance. Abbreviations as in Figures 1 and 4.not be true for certain valve combinations such as
Trifecta 21 and Sapien XT 23, where the respective
heights are 16 and 14 mm. This may, theoretically,
result in leaﬂet overhang. The hemodynamic relevance
of this is, however, unknown. This needs further
investigation and also highlights the complexities of a
VIV procedure.
3. Although we have measured only the aortic SHV, the
same principle should apply to SHV designed for
mitral and tricuspid implantation. In the mitral posi-
tion, however, a larger oversizing may be essential to
prevent delayed embolization in the atrium (20,21) as
a result of the larger closing pressures to which it is
subjected. Also, larger oversizing may not be a prob-
lem in mitral implantations because the mitral SHV
are usually of larger sizes, and there is no risk of cor-
onary obstruction. We feel that when considering
mitral VIV using Sapien/Sapien XT THV, one should
use the stent ID rather than the true ID to achieve this
oversize. This will lead to a conical/ﬂared deployment,
which prevents atrial migration (20).
Study limitations. We tested unused SHV, and hence, they
lacked the calciﬁcation or thickening seen in degenerated
SHV. This should be taken into account when deciding
a size of THV, especially in an SHV with a borderline ID.
Table 2. Dimensions of Various Bioprostheses and Recommended THV Sizes Based on True ID Measurements
Stented SHV
Valve Name Size (mm) Stent ID True ID Sapien XT CoreValve*
P 2700 19 18.0 17.0 NR NR
21 20.0 19.0 23 23
23 22.0 21.0 23 26
25 24.0 23.0 26 26/29
27 26.0 25.0 29 29
29 28.0 27.0 29 31
Perimount 19 18.0 17.0 NR NR
21 20.0 19.0 23 23
23 22.0 21.0 23 26
25 24.0 23.0 26 26/29
27 26.0 25.0 29 29
29 28.0 27.0 29 31
Magna 19 18.0 17.0 NR NR
21 20.0 19.0 23 23
23 22.0 21.0 23 26
25 24.0 23.0 26 26/29
27 26.0 25.0 29 29
29 28.0 27.0 29 31
CE standard 19 17.0 17.0 NR NR
21 19.0 18.0 23 23
23 21.0 20.0 23 23
25 23.0 21.0 23 26
27 25.0 23.0 26 26
29 27.0 25.0 29 29
31 29.0 27.0 29 31
CE S.A.V. 19 18.0 17.0 NR NR
21 20.0 19.5 23 23
23 22.0 21.0 23 26
25 24.0 22.5 26 26/29
27 26.0 24.0 26 29
29 28.0 25.0 29 29/31
31 30.0 27.0 29 31
Mosaic 19 17.5 15.5 NR NR
21 18.5 16.5 NR NR
23 20.5 18.5 23 23
25 22.5 20.5 23 26
27 24.0 22.0 26 26
29 26.0 24.0 26 29
Hancock II 19 17.5 15.5 NR NR
21 18.5 16.5 NR NR
23 20.5 18.5 23 23
25 22.5 20.5 23 26
27 24.0 22.0 26 26
29 26.0 24.0 26 29
Epic 21 19.0 16.5 NR NR
23 21.0 18.5 23 23
25 23.0 20.5 23 26
27 25.0 22.5 26 26
29 27.0 24.5 26 29
Continued on the next page
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Table 2. Continued
Stented SHV
Valve Name Size (mm) Stent ID True ID Sapien XT CoreValve*
Epic Supra 19 19.0 16.5 NR NR
21 21.0 18.5 23 23
23 23.0 20.5 23 26
25 25.0 22.5 26 26
27 27.0 24.5 26 29
Trifecta 19 17.0 16.0 NR NR
21 19.0 18.0 23 23
23 21.0 20.5 23 26
25 23.0 22.0 26 26
27 25.0 24.0 26 29
29 27.0 26.0 29 31
Mitroﬂow 19 15.4 15.5 NR NR
21 17.3 17.0 NR NR
23 19.0 19.0 23 23
25 21.0 21.0 23 26
27 22.9 23.0 26 26
29 24.7 24.5 26 29
Soprano 18 17.8 18.0 23 23
20 19.8 20.0 23 23
22 21.7 22.0 26 26
24 23.7 23.5 26 29
26 25.6 25.5 29 29
28 27.6 27.5 29 31
Aspire 20 18.2 16.5 NR NR
21 19.2 17.5 NR NR
23 21.0 19.0 23 23
25 23.0 20.0 23 23
27 25.0 22.0 26 26
Stentless SHV
Valve Name Size (mm)
Tissue Annulus
Diameter True ID Sapien XT CoreValve
Prima 19 19 17.5 NR NR
21 21 19.5 23 23
23 23 21.5 23/26 26
25 25 23.5 26 26/29
27 27 25.5 29 29
29 29 27.5 29 31
Freestyle 19 19 16 NR NR
21 21 18 23 23
23 23 20 23 23
25 25 22 26 26
27 27 25 29 29
Toronto SPV 19 19 17 NR NR
21 21 19 23 23
23 23 21 23 26
25 25 23 26 26/29
27 27 25 29 29
29 29 27 29 31
When a valve is not recommended (NR), this recommendation is based on sizing guidance of the currently available THV valves for the native
aortic annulus diameter. It may be still feasible to perform a VIV, but this may result in suboptimal results such as higher residual gradients and/or
leaﬂet malfunction. *The 23 size in the CoreValve column represents the Evolut THV.
ID ¼ internal diameter; THV ¼ transcatheter heart valve; other abbreviations as in Table 1.
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Figure 6. Effect of Leaﬂet Type and Mounting on the Stent ID
(A) Porcine valves: true internal diameter (ID) is at least 2 mm less than the stent ID. (B) Pericardial valves with leaﬂets sutured inside the stent frame: true ID is at least
1 mm less than the stent ID. (C) Pericardial valves with leaﬂets sutured outside the stent frame: true ID is the same as the stent ID.
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tricuspid and pulmonary positions, and because the right-
sided pressures are low, there could be an argument for using
a smaller THV rather than larger in a borderline case.
Another factor that can affect the true ID in a clinical sce-
nario is pannus. However, both calciﬁcation and pannus can
be easily evaluated by echocardiography and CT scan; at
worst, the ID is going to be less than the true ID, but never
more.
Conclusions
Design features of SHV may lead to a reduction in the stent
ID in the majority of SHV. It is important to identify the
SHV design so as to take this reduction into considerationFigure 7. Fluoroscopic Conﬁrmation of the Effect of Leaﬂet Type and Mounting o
The outer thin arrows point to the ﬂuoroscopic stent frame of the SHV, and the inner
CoreValve (size 26) implanted within CE Porcine standard SHV (size 25) demonstrate
frame of the CE and CoreValve bioprostheses. (B) CoreValve (size 26) implanted with
radio-opaque stent frame of the Perimount and CoreValve. (C) CoreValve (size 26) im
opaque stent frame of the Trifecta and CoreValve. Abbreviations as in Figures 1 andwhen choosing the appropriate THV during a VIV proce-
dure. The true ID chart in this paper provides realistic ID
measurements for VIV treatment in the aortic position. One
should use the true ID for selecting an appropriate THV
device in the aortic position, but use the stent ID to choose
the device for a mitral VIV procedure. If the SHV size is not
known, balloon aortic valvuloplasty may be the best way to
conﬁrm the true ID, because ID measurements obtained by
other modalities may be inaccurate.
Acknowledgments
The authors thank Miss Maya Guthrie and Mrs. Shalina
Sunni for their help in obtaining ﬂuoroscopic images
required for the paper, and Mrs. Urmi Bapat for editorial
assistance.n the Stent ID
thick arrows point to the inﬂow portion of the stent frame of the CoreValve. (A)
d greater degree of separation (at least 2 mm) between the radio-opaque stent
in Perimount (size 25), demonstrated 1-mm degree of separation between the
planted within Trifecta (size 25) demonstrated no separation between the radio-
3.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 2 , 2 0 1 4 Bapat et al.
F E B R U A R Y 2 0 1 4 : 1 1 5 – 2 7 True ID of a Surgical Heart Valve
127Reprint requests and correspondence: Mr. Vinayak (Vinnie) N.
Bapat, 6th Floor East Wing, Department of Cardiothoracic
Surgery, St. Thomas’ Hospital, Westminster Bridge Road, London
SE1 7EH, United Kingdom. E-mail: vnbapat@yahoo.com.REFERENCES
1. Généreux P, Head SJ, Wood DA, et al. Transcatheter aortic valve
implantation: 10-year anniversary part II: clinical implications. Eur
Heart J 2012;33:2399–402.
2. Bapat V, Attia R, Redwood S, et al. Use of transcatheter heart valves for
a valve-in-valve implantation in patients with degenerated aortic bio-
prosthesis: technical considerations and results. J Thorac Cardiovasc
Surg 2012;144:1372–9.
3. Gurvitch R, Cheung A, Ye J, et al. Transcatheter valve-in-valve im-
plantation for failed surgical bioprosthetic valves. J Am Coll Cardiol
2011;58:2196–209.
4. Khawaja MZ, Haworth P, Ghuran A, et al. Transcatheter aortic valve
implantation for stenosed and regurgitant aortic valve bioprosthesis:
CoreValve for failed bioprosthetic aortic valve replacements. J Am Coll
Cardiol 2010;55:97–101.
5. Piazza N, Bleiziffer S, Brockmann G, et al. Transcatheter aortic valve
implantation for failing surgical aortic bioprosthetic valve: from concept
to clinical application and evaluation (part 2). J Am Coll Cardiol Intv
2011;4:733–42.
6. Latib A, Ielasi A, Montorfano M, et al. Transcatheter valve-in-valve
implantation with the Edwards SAPIEN in patients with bioprosthetic
heart valve failure: the Milan experience. EuroIntervention 2012;7:
1275–84.
7. Gotzmann M, Mugge A, Bojara W. Transcatheter aortic valve im-
plantation for treatment of patients with degenerated aortic bio-
prostheses: valve-in-valve technique. Catheter Cardiovasc Interv 2010;
26:1000–6.
8. Pasic M, Unbehaun A, Dreysse S, et al. Transapical aortic valve im-
plantation after previous aortic valve replacement: clinical proof of the
“valve-in-valve” concept. J Thorac Cardiovasc Surg 2011;142:270–7.
9. Seiffert M, Franzen O, Conradi L, et al. Series of transcatheter valve-
in-valve implantations in high-risk patients with degenerated bio-
prostheses in aortic and mitral position. Catheter Cardiovasc Interv
2010;76:608–15.10. Cheung A, Soon JL, Webb JG, Ye J. Transatrial transcatheter tricuspid
valve-in-valve technique. J Card Surg 2012;27:196–8.
11. Faza N, Kenny D, Kavinsky C, Amin Z, Heitschmidt M, Hijazi Z.
Single center comparative outcomes of the Edwards SAPIEN and
Medtronic Melody transcatheter heart valves in the pulmonary position.
Catheter Cardiovasc Interv 2013;82:E535–41.
12. Ng AC, Delgado V, van der Kley F, et al. Comparison of aortic root
dimensions and geometries before and after transcatheter aortic valve
implantation by 2-and 3-dimmensional transesophageal echocardiog-
raphy and multislice computed tomography. Circ Cardiovasc Imaging
2010;3:94–102.
13. Bapat V, Chadalavada S, Tehrani H, Attia R, Thomas M. A guide to
ﬂuoroscopic identiﬁcation and design of bioprosthetic valves: a refer-
ence for valve-in-valve procedure. Catheter Cardiovasc Interv 2013;81:
853–61.
14. Dvir D, Webb J, Brecker S, et al. Transcatheter aortic valve replacement
for degenerative bioprosthetic surgical valves: results from the global
valve-in-valve registry. Circulation 2012;126:2335–44.
15. Babaliaros VC, Jungadhwalla Z, Lerakis S, et al. Use of balloon aortic
valvuloplasty to size the aortic annulus before implantation of a balloon-
expandable heart valve. J Am Coll Cardiol Intv 2010;3:114–8.
16. Gurvitch R, Cheung A, Bedogni F, Webb JG. Coronary obstruction
following transcatheter aortic valve-in-valve implantation for failed
surgical bioprosthesis. Catheter Cardiovasc Interv 2011;77:439–44.
17. Gonzalo BC, Jorge SF, Nicolas VG. Acute coronary artery occlusions
complicating a valve-in-valve procedure. Heart 2013;99:591–2.
18. Funder JA, Frost MW, Klaaborg KE, et al. Aortic root distensibility
after subcoronary stentless valve implantation. J Heart Valve Dis 2012;
21:181–8.
19. Chakravarty T, Jilahawi H, Nakamura M, et al. Pre-emptive positioning
of a coronary stent in the left-anterior descending artery for a left main
protection: a prerequisite for transcatheter aortic valve-in-valve im-
plantation for failing stentless bioprosthesis? Catheter Cardiovasc Interv
2013;82:E630–6.
20. Bapat V, Khaliel F, Ihleberg L. Delayed migration of Sapien valve
following a transcatheter mitral valve-in-valve implantation. Catheter
Cardiovasc Interv 2014;83:E150–4.
21. Cheung A, Webb JG, Barbanti M, et al. 5-year experience with
transcatheter transapical mitral valve-in-valve implantation for bio-
prosthetic valve dysfunction. J Am Coll Cardiol 2013;61:1759–66.
Key Words: heart valve - valve replacement -
valve-in-valve.
